Immunotherapy has emerged as a powerful therapeutic approach in many areas of clinical oncology and hematology. The approval ipilimumab, monoclonal antibody targeting the immune cell receptor CTLA-4, marked beginning era checkpoint inhibitors. In meantime, numerous antibodies PD-1 pathway have expanded class clinically approved Furthermore, novel directed against other checkpoints are currently...